Genetic basis and gene therapy trials for thyroid cancer

Cancer Genomics and Proteomics

Volumn 7, Issue 1, 2010, Pages 31-49

  Al Humadi, Hussam ^a   Zarros, Apostolos ^a   Al Saigh, Rafal ^a   Liapi, Charis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antisense approach; Combination approach; Gene therapy trials; Genetic basis; Mutations; Review; Thyroid cancer; Toxic gene therapy approach

Indexed keywords

ADENOVIRUS VECTOR; APC PROTEIN; B RAF KINASE; BETA CATENIN; CRE RECOMBINASE; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G 207; GANCICLOVIR; GLOBAL RECEPTOR INVOLVED IN MYOGENESIS 1; INTERLEUKIN 12; INTERLEUKIN 2; NEUROTROPHIC RECEPTOR TYROSINE KINASE 1; ONCOLYTIC VIRUS; ONYX 015; ONYX 411; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE KINASE; RECEPTOR; RIBOZYME; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; THYMIDINE KINASE; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPLASTIC CARCINOMA; ANTISENSE THERAPY; CANCER GENE THERAPY; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; EPIGENETICS; FUSION GENE; GENE AMPLIFICATION; GENE DELIVERY SYSTEM; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE TARGETING; HUMAN; LOXP SITE; NONHUMAN; ONCOGENE RAS; ONCOLYTIC VIROTHERAPY; POINT MUTATION; REVIEW; RIBOZYME THERAPY; SUICIDE GENE; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR GENE; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

EID: 77949592914     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Thyroid Carcinoma Task Force: AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 7: 202-220, 2001.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
3. Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167, 2006.
4. Strachan MWJ and Walker BR: Endocrine disease: Davidson's Principles and Practice of Medicine. 20th ed. Philadelphia, PA: Churchill Livingstone Elsevier, 2006.
5. Hölzer S and Dudeck J: Patient care evaluation studies - a comprehensive concept for evaluation of oncologic patient management. Z Arztl Fortbild Qualitatssich 94: 121-126, 2000.
6. DeGroot LJ and Zhang R: Clinical review 131: Gene therapy for thyroid cancer: where do we stand? J Clin Endocrinol Metab 86: 2923-2928, 2001.
7. Patel KN and Singh B: Genetic considerations in thyroid cancer. Cancer Control 13: 111-118, 2006.
8. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19: 545-576, 1990.
9. Shaha AR, Shah JP and Loree TR: Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 3: 534-538, 1996.
10. Shaha AR, Loree TR and Shah JP: Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118: 1131-1138, 1995.
11. Giuffrida D and Gharib H: Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11: 1083-1089, 2000.
12. Ain KB: Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8: 715-726, 1998.
13. Ain KB: Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16: 64-69, 1999.
14. Hölting T, Möller P, Tschahargane C, Meybier H, Buhr H and Herfarth C: Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg 14: 291-295, 1990.
15. Kebebew E, Ituarte PH, Siperstein AE, Duh QY and Clark OH: Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88: 1139-1148, 2000.
16. Ball DW: Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 19: 18-23, 2007.
17. Moley JF: Medullary thyroid carcinoma. Curr Treat Options Oncol 4: 339-347, 2003.
18. Ward LS, Morari EC, Leite JL, Bufalo NE, Guilhen AC, Araujo PP, Tincani AJ, Assumpção LV and Matos PS: Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol 51: 713-722, 2007.
19. Knobel M and Medeiros-Neto G: Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq Bras Endocrinol Metabol 51: 701-712, 2007.
20. Nikiforov Y and Gnepp DR: Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer 74: 748-766, 1994.
21. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigier HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
22. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934, 2002.
23. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J and Rapp UR: The ins and outs of Raf kinases. Trends Biochem Sci 19: 474-480, 1994.
24. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
25. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D and Ladenson PW: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373-6379, 2005.
26. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D and Xing M: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90: 4688-4693, 2005.
27. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J and Santoro M: Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65: 10199-10207, 2005.
28. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V and Xing M: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13: 1161-1170, 2007.
29. Takahashi M, Ritz J and Cooper GM: Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 42: 581-588, 1985.
30. LiVolsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho-Simões M, Wenig B, DeLellis RA, Cady B, Mazzaferri EL, Hay I, Fagin JA, Weber AL, Caruso P, Voutilainen PE, Franssila KO, Williams ED, Schneider AB, Nikiforov Y, Rabes HM, Akslen L, Ezzat S, Santoro M, Eng C and Harach HR: Papillary carcinoma. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds.). Lyon: IARC Press, pp. 57-66, 2004.
31. Nikiforov YE: RETIPTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16, 2002.
32. Greco A, Roccato E and Pierotti MA: TRK oncogenes in papillary thyroid carcinoma. Cancer Treat Res 122: 207-219, 2004.
33. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM and Fletcher JA: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289: 1357-1360, 2000.
34. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG and Nikiforov YE: PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26: 1016-1023, 2002.
35. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N and Akiyama M: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369-1371, 1992.
36. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993.
37. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T and Machinami R: Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17: 375-381, 1993.
38. Donghi R, Longoni A, Pilotti S, Michieli P, Delia Porta G and Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753-1760, 1993.
39. Matias-Guiu X, Cuatrecasas M, Musulen E and Prat J: p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47: 337-339, 1994.
40. Salvatore D, Celetti A, Fabien N, Paulin C, Martelli ML, Battaglia C, Califano D, Monaco C, Viglietto G, Santoro M and Fusco A: Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 134: 177-183, 1996.
41. Battista S, Martelli ML, Fedele M, Chiappetta G, Trapasso F, De Vita G, Battaglia C, Santoro M, Viglietto G, Fagin JA and Fusco A: A mutated p53 gene alters thyroid cell differentiation. Oncogene 11: 2029-2037, 1995.
42. Fusco A and Santoro M: Human thyroid carcinogenesis. Forum 7: 214-229, 1997.
43. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL and Tallini G: Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158: 987-996, 2001.
44. Cetta F, Montalto G, Gori M, Curia MC, Cama A and Olschwang S: Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 85: 286-292, 2000.
45. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D and Sobrinho-Simôes M: Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 92: 1892-1898, 2005.
46. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H and Eng C: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156: 1693-1700, 2000.
47. Simpson L and Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res 264: 29-41, 2001.
48. Gimm O: Thyroid cancer. Cancer Lett 163: 143-156, 2001.
49. Xing M: Gene methylation in thyroid tumorigenesis. Endocrinology 148: 948-953, 2007.
50. Bell B and Mazzaferri EL: Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci 38: 185-190, 1993.
51. Hover AR, Cawthern T and McDanial W: Cowden disease. A hereditary polyposis syndrome diagnosable by mucocutaneous inspection. J Clin Gastroenterol 8: 576-579, 1986.
52. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, Finniear R, Markham A, Groffen J, Boguski MS, Altschul SF, Horii A, Ando H, Miyoshi Y, Miki Y, Nishisho I and Nakamura Y: Identification of FAP locus genes from chromosome 5q21. Science 253: 661-665, 1991.
53. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253: 665-669, 1991.
54. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C and Parsons R: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67, 1997.
55. Ciampi R and Nikiforov YE: Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16: 163-172, 2005.
56. Trovisco V, Soares P and Sobrinho-Simões M: B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 37: 781-786, 2006.
57. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG and Nikiforov YE: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326, 2003.
58. Rosai J: Handling of thyroid follicular patterned lesions. Endocr Pathol 16: 279-283, 2005.
59. DeLellis RA: Pathology and genetics of thyroid carcinoma. J Surg Oncol 94: 662-669, 2006.
60. Tallini G and Asa SL: RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8: 345-354, 2001.
61. Quiros RM, Ding HG, Gattuso P, Prinz RA and Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103: 2261-2268, 2005.
62. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457, 2003.
63. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S and Pierotti MA: RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4: 223-228, 1998.
64. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D and Klugbauer S: Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6: 1093-1103, 2000.
65. Namba H, Rubin SA and Fagin JA: Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474-1479, 1990.
66. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M and Prat J: Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5: 45-52, 1996.
67. La Perle KM, Jhiang SM and Capen CC: Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157: 671-677, 2000.
68. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG and Leite V: Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87: 3947-3952, 2002.
69. Máximo V, Soares P, Lima J, Cameselle-Teijeiro J and Sobrinho-Simões M: Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol 160: 1857-1865, 2002.
70. Takeuchi Y, Daa T, Kashima K, Yokoyama S, Nakayama I and Noguchi S: Mutations of p53 in thyroid carcinoma with an insular component. Thyroid 9: 377-381, 1999.
71. Gimm O, Morrison CD, Suster S, Komminoth P, Mulligan L and Sweet KM: Multiple endocrine neoplasia type 2. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds.). Lyon: IARC Press, pp. 211-217, 2004.
72. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ and Mulligan LM: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 276: 1575-1579, 1996.
73. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS and Gagel RF: Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81: 3740-3745, 1996.
74. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D and Bendlova B: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284: 21-27, 2008.
75. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
76. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML and Fusco A: RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4: 287-294, 1998.
77. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L and Fagin JA: Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instabUity in thyroid PCCL3 cells. Cancer Res 65: 2465-2473, 2005.
78. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Höög A, Frisk T, Larsson C and Zedenius J: Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88: 4440-4445, 2003.
79. Farid NR, Shi Y and Zou M: Molecular basis of thyroid cancer. Endocr Rev 15: 202-232, 1994.
80. Takano T and Amino N: Molecular-based diagnosis of thyroid carcinomas by detecting cancer-specific mRNAs. Rinsho Byori 48: 149-154, 2000.
81. Takano T: Fetal cell carcinogenesis of the thyroid: a hypothesis for better understanding of gene expression profile and genomic alternation in thyroid carcinoma. Endocr J 51: 509-515, 2004.
82. Messina M, Yu DM, Learoyd DL, Both GW, Molloy PL and Robinson BG: High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line. Mol Cell Endocrinol 164: 219-224, 2000.
83. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA and Curiel DT: Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57: 1447-1451, 1997.
84. Böckmann M, Drosten M and Pützer BM: Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med 7: 179-188, 2005.
85. Böckmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BA and Pützer BM: Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Hum Gene Ther 16: 1267-1275, 2005.
86. Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S and Niwa M: Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res 59: 3049-3052, 1999.
87. Nishihara E, Nagayama Y, Mawatari F, Tanaka K, Namba H, Niwa M and Yamashita S: Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 138: 4577-4583, 1997.
88. Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M and Yamashita S: Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology 139: 3996-3999, 1998.
89. Zhang R, Straus FH and DeGroot LJ: Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 11: 115-123, 2001.
90. Zhang R and DeGroot LJ: Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy. Thyroid 10: 313-319, 2000.
91. Zhang R, Baunoch D and DeGroot LJ: Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murineinterleukin-2 gene. Thyroid 8: 1137-1146, 1998.
92. Zhang R, Straus FH and DeGroot LJ: Effective genetic therapy of established medullary thyroid carcinomas with murineinterleukin-2: dissemination and cytotoxicity studies in a rat tumor model. Endocrinology 140: 2152-2158, 1999.
93. Lausson S, Fournes B, Borrel C, Milhaud G and Treilhou-Lahille F: Immune response against medullary thyroid carcinoma (MTC) induced by parentaland/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol Immunother 43: 116-123, 1996.
94. Zhang R and DeGroot LJ: Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model. Clin Endocrinol (Oxf) 52: 687-694, 2000.
95. Yamazaki M, Zhang R, Straus FH, Messina M, Robinson BG, Hashizume K and DeGroot LJ: Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther 9: 64-74, 2002.
96. Zhang R and DeGroot LJ: Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12. Endocrinology 144: 1393-1398, 2003.
97. Soler MN, Milhaud G, Lekmine F, Treilhou-Lahille F, Klatzmann D and Lausson S: Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol Immunother 48: 91-99, 1999.
98. Zhang R and DeGroot LJ: An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. Endocr Relat Cancer 8: 315-325, 2001.
99. Yamazaki M, Straus FH, Messina M, Robinson BG, Takeda T, Hashizume K and DeGroot LJ: Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther 11: 8-15, 2004.
100. Barzon L, Bonaguro R, Castagliuolo I, Chilosi M, Franchin E, Del Vecchio C, Giaretta I, Boscaro M and Palù G: Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 148: 73-80, 2003.
101. Barzon L, Bonaguro R, Castagliuolo I, Chilosi M, Gnatta E, Parolin C, Boscaro M and Palù G: Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. J Clin Endocrinol Metab 87: 5304-5311, 2002.
102. Barzon L, Pacenti M, Taccaliti A, Franchin E, Bruglia M, Boscaro M and Palù G: A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J Clin Endocrinol Metab 90: 2831-2834, 2005.
103. Messina M, Yu DM, Both GW, Molloy PL and Robinson BG: Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells. J Clin Endocrinol Metab 88: 1310-1318, 2003.
104. Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmüller L and Deppert W: Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18: 7706-7717, 1999.
105. Lakin ND and Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655, 1999.
106. McCormick F: Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1: 130-141, 2001.
107. Nagayama Y, Shigematsu K, Namba H, Zeki K, Yamashita S and Niwa M: Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res 20: 2723-2728, 2000.
108. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A and Pontecorvi A: p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14: 729-740, 1997.
109. Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A and Gonsky R: Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 56: 765-771, 1996.
110. Imanishi R, Ohtsuru A, Iwamatsu M, Iioka T, Namba H, Seto S, Yano K and Yamashita S: A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab 87: 4821-4824, 2002.
111. Moretti F, Nanni S, Farsetti A, Narducci M, Crescenzi M, Giuliacci S, Sacchi A and Pontecorvi A: Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 85: 302-308, 2000.
112. Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang TT, Ohtsuru A, Namba H, Yamashita S, Ayabe H and Niwa M: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83: 3668-3672, 1998.
113. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S and Niwa M: Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85: 4081-4086, 2000.
114. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE and Fojo T: Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83: 2516-2522, 1998.
115. Kim SB, Ahn IM, Park HJ, Park JS, Cho HJ, Gong G, Suh C, Lee JS, Kim WK and Kim SH: Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck 23: 223-229, 2001.
116. Drosten M, Frilling A, Stiewe T and Pützer BM: A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery 132: 991-997, 2002.
117. Drosten M, Stiewe T and Pützer BM: Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 14: 971-982, 2003.
118. Chun YS, Saji M and Zeiger MA: Overexpression of TTF-1 and PAX-8 restores thyroglobulin gene promoter activity in ARO and WRO cell lines. Surgery 124: 1100-1105, 1998.
119. Shimura H, Suzuki H, Miyazaki A, Furuya F, Ohta K, Haraguchi K, Endo T and Onaya T: Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res 61: 3640-3646, 2001.
120. Chung HK, Yi YW, Jung NC, Kim D, Suh JM, Kim H, Park KC, Kim DW, Hwang ES, Song JH, Ku BJ, Han HJ, Ro HK, Kim JM and Shong M: Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. J Clin Endocrinol Metab 88: 3913-3920, 2003.
121. Hennige AM, Lammers R, Höppner W, Arlt D, Strack V, Teichmann R, Machicao F, Ullrich A, Häring HU and Kellerer M: Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 142: 4441-4447, 2001.
122. Qiao S, Iwashita T, Furukawa T, Yamamoto M, Sobue G and Takahashi M: Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins. J Biol Chem 276: 9460-9467, 2001.
123. Iuliano R, Trapasso F, Le Pera I, Schepis F, Samà I, Clodomiro A, Dumon KR, Santoro M, Chiariotti L, Viglietto G and Fusco A: An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res 63: 882-886, 2003.
124. Scala S, Portella G, Fedele M, Chiappetta G and Fusco A: Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 97: 4256-4261, 2000.
125. Hassan I, Wunderlich A, Burchert A, Hoffmann S and ZieUce A: Antisense p53 oligonucleotides inhibit proliferation and induce chemosensitivity in follicular thyroid cancer cells. Anticancer Res 26: 1171-1176, 2006.
126. Parthasarathy R, Cote GJ and Gagel RF: Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 59: 3911-3914, 1999.
127. Du ZX, Zhang HY, Gao da X, Wang HQ, Li YJ and Liu GL: Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Exp Mol Med 38: 230-240, 2006.
128. Nagayama Y, Nishihara E, Namba H, Yokoi H, Hasegawa M, Mizuguchi H, Hayakawa T, Hamada H, Yamashita S and Niwa M: Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/IoxP system. Cancer Gene Ther 8: 36-44, 2001.
129. Portella G, Scala S, Vitagliano D, Vecchio G and Fusco A: ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 87: 2525-2531, 2002.
130. 130Crompton AM and Kirn DH: From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 7: 133-139, 2007.
131. Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976, 2005.
132. Kruyt FA and Curiel DT: Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 13: 485-495, 2002.
133. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645, 1997.
134. Abbosh PH, Li X, Li L, Gardner TA, Kao C and Nephew KP: A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Ther 14: 399-408, 2007.
135. Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK and Eberhardt NL: ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther 15: 750-757, 2008.
136. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
137. Teodoro JG, Shore GC and Branton PE: Adenovirus ElA proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene 11: 467-474, 1995.
138. Zhou Z, Jia SF, Hung MC and Kleinerman ES: E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 61: 3394-3398, 2001.
139. Kim KI, Rang JH, Chung JK, Lee YJ, Jeong JM, Lee DS and Lee MC: Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 48: 1553-1561, 2007.
140. Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M and Fusco A: ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88: 5027-5032, 2003.
141. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A and Portella G: Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 148: 5186-5194, 2007.
142. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641, 2004.
143. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003.
144. Wang CY, Zhong WB, Chang TC, Lai SM and Tsai YF: Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88: 3021-3026, 2003.
145. Zhong WB, Wang CY, Chang TC and Lee WS: Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144: 3852-3859, 2003.
146. Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P, Huang YY, Fong Y and Wong RJ: Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res 14: 1519-1528, 2008.
147. Carrasco N: Iodide transport in the thyroid gland. Biochim Biophys Acta 1154: 65-82, 1993.
148. Dai G, Levy O and Carrasco N: Cloning and characterization of the thyroid iodide transporter. Nature 379: 458-460, 1996.
149. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL and Jhiang SM: Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226: 339-345, 1996.
150. Hertz S and Roberts A: Radioactive iodine as an indicator in thyroid physiology. V. The use of radioactive iodine in the differential diagnosis of two types of Graves' disease. J Clin Invest 21: 31-32, 1942.
151. Thomas-Morvan C, Carayon P, Schlumberger M, Vignal A and Tubiana M: Thyrotrophin stimulation of adenylate cyclase and iodine uptake in human differentiated thyroid cancer. Acta Endocrinol (Copenh) 101: 25-31, 1982.
152. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL and Jhiang SM: Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138: 3555-3558, 1997.
153. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG and Filetti S: Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83: 2493-2496, 1998.
154. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84: 3228-3234, 1999.
155. - symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83: 4102-4106, 1998.
156. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A and Onaya T: Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101: 1296-1300, 1998.
157. - symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86: 2697-2700, 2001.
158. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohán O and Carrasco N: Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88: 1880-1888, 2003.
159. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS and Carrasco N: The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24: 48-77, 2003.
160. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY and Morris JC: Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 59: 2136-2141, 1999.
161. Mandell RB, Mandell LZ and Link CJ Jr: Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59: 661-668, 1999.
162. Spitzweg C, Baker CH, Bergert ER, O'Connor MK and Morris JC: Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 18: 916-924, 2007.
163. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S, Schlumberger M and Perricaudet M: Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60: 3484-3492, 2000.
164. Dingli D, Russell SJ and Morris JC 3rd: In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 90: 1079-1086, 2003.
165. - symporter gene. Endocrinology 38: 4493-4496, 1997.
166. Smit JW, Shröder-van der Elst JP, Karperien M, Que I, van der Pluijm G, Goslings B, Romijn JA and van der Heide D: Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 10: 939-943, 2000.
167. Petrich T, Knapp WH and Pötter E: Functional activity of human sodium/iodide symporter in tumor cell lines. Nuklearmedizin 42: 15-18, 2003.
168. Lee WW, Lee B, Kim SJ, Jin J, Moon DH and Lee H: Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol Rep 10: 845-849, 2003.
169. Hsieh YJ, Ke CC, Liu RS, Wang FH, Tang KT, Chi CW, Chen FD and Lee CH: Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter. Anticancer Res 27: 2515-2522, 2007.
170. Ward LS, Santarosa PL, Granja F, da Assumpção LV, Savoldi M and Goldman GH: Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett 200: 85-91, 2003.
171. - targeting to the membrane. Endocr Relat Cancer 13: 257-269, 2006.